Specifically, the research found that it is not uncommon for women to have prolonged bleeding of 10 or more days, spotting for six or more days and/or heavy bleeding for three or more days during the transition. In fact, of the more than 1,300 women ages 42-52 in the study, 91 percent recorded 1-3 occurrences in a three-year period of bleeding that lasted 10 or more days, nearly 88 percent reported six or more days of spotting, and close to 78 percent recorded three or more days of heavy flow. More than a quarter of the women had as many as three episodes of the 10+ days of bleeding in a six-month period.
The most commonly reported injection site related adverse reaction was pain. The majority of these reactions were reported to be of mild to moderate severity. Subject evaluations of injection site pain based on a visual analogue scale tended to lessen in frequency and intensity over time in all Phase 2 and 3 studies with Xeplion. Injections into the deltoid were perceived as slightly more painful than corresponding gluteal injections. Other injection site reactions were mostly mild in intensity and included induration (common), pruritus (uncommon) and nodules (rare).